Topological Control of p21WAF1/CIP1 Expression in Normal and Neoplastic Tissues

Cancer Research

Volumn 55, Issue 13, 1995, Pages 2910-2919

  El Deiry, Wafik S ^a,b   Tokino, Takashi ^a   Waldman, Todd ^a   Oliner, Jon D ^a   Velculescu, Victor E ^a   Burrell, Marilee ^c   Hill, David E ^c   Healy, Eugene ^d   Rees, Jonathan L ^d   Hamilton, Stanley R ^a   Kinzler, Kenneth W ^a   Vogelstein, Bert ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Oncogene Science   (United States)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; CIP1 PROTEIN; CYCLINE; MESSENGER RNA; MONOCLONAL ANTIBODY; PRIMER DNA; PROTEIN P53;

ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON TUMOR; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; ADENOMA; ANIMAL; CARCINOMA; CHEMISTRY; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOLECULAR GENETICS; MOUSE STRAIN; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RAT; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SKIN;

ADENOMA; ANIMAL; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CARCINOMA; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; CYCLINS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); PROTEIN P53; RATS; RNA, MESSENGER; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, NUCLEIC ACID; SKIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TRANSCRIPTION, GENETIC;

EID: 0028981086     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. 1 phase progression: cycling on cue. Cell, 79: 551–555, 1994.
2. Hunter, T., and Pines, J. Cyclins and Cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 79: 573–582, 1994.
3. Xiong, Y., Zhang, H., and Beach, D. D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell, 71: 505–514, 1992.
4. Xiong, Y., Zhang, H., and Beach, D. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev., 7: 1572–1583, 1993.
5. 1 cyclin-dependent kinases. Cell, 75: 805–816, 1993.
6. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 704, 1993.
7. Gu, Y., Turck, C. W., and Morgan, D. O. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature (Lond.), 366: 707–710, 1993.
8. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704–707, 1993.
9. INK4B is a potential effector of TGF-beta-induccd cell cycle arrest. Nature (Lond.), 371: 257–261, 1994.
10. INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev., 8: 2939–2952, 1994.
11. Kip1, a cyclin-cdk inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59–66, 1994.
12. Toyoshima, H., and Hunter, T. p27, a novel inhibitor of Gl cyclin-Cdk protein kinase activity, is related to p21. Cell, 78: 67–74, 1994.
13. KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9: 639–649, 1995.
14. CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650–662, 1995.
15. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinder, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817–825, 1993.
16. Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., and Smith, J. R. Qoning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res., 211: 90–98, 1994.
17. Li, R., Waga, S., Hannon, G. J., Beach, D., and Stillman, B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature (Lond.), 371: 534–537, 1994.
18. Flores-Rozas, H., Kelman, Z., Dean, F. B., Pan, Z. Q., Harper, J. W., Elledge, S. J., O'Donnell, M., and Hurwitz, J. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. Proc. Natl. Acad. Sci. USA, 91: 8655–8659, 1994.
19. Kip1, to regions involved in human cancer. Cancer Res., 55: 1199–1205, 1995.
20. Kip1 gene to 12pl3 and its analysis in leukemias. Cancer Res., 55: 1206–1210, 1995.
21. Kip1. chromosomal mapping to 12pl2–12pl3.1 and absence of mutations in human tumors. Cancer Res., 55: 1211–1214, 1995.
22. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavttigian, S. V., Stockert, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436–440, 1994.
23. Kamb, A., Shattuck-Eidens, D., Eeles, R., et al. Analysis of the pl6 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet., 8: 23–26, 1994.
24. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753–756, 1994.
25. Hussussian, C. J., StruewinC., J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline pl6 mutations in familial melanoma. Nat. Genet., 8: 15–21, 1994.
26. Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W., and Vogelstein, B. Deletion of pi6 and pi5 genes in brain tumors. Cancer Res., 54: 6353–6358, 1994.
27. Devine, S. E., and Boeke, J. D. Efficient integration of artificial transposons into plasmid targets in vitro: a useful tool for DNA mappinC., sequencing and genetic analysis. Nucleic Acids Res., 22: 3765–3772, 1994.
28. Fridovich-Keil, J. L., Gudas, J. M., Bryan, I. B., and Pardee, A. B. Improved expression vectors for eukaryotic promoter/enhancer studies. Biotechniques, 11: 572–579,1991.
29. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W., and Vogelstein, B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Washington DC), 256: 827–830, 1992.
30. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet., 1: 45–49, 1992.
31. Smith, K. J., Johnson, K. A., Bryan, T. M., Hill, D. E., Markowitz, S., Willson, J. K. V., Paraskeva, C., Peterson, G. M., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. The APC gene product in normal and tumor cells. Proc. Natl. Acad. Sci. USA, 90: 2846–2850, 1993.
32. Campbell, C., Quinn, A. G., Angus, B., Farr, P. M., and Rees, J. L. Wavelength specific patterns of p53 induction in human skin following exposure to ultraviolet radiation. Cancer Res., 53: 2697–2699, 1993.
33. Mercer, W. E., Shields, M. T., Amin, M., Sauve, G. J., Appella, E., Romano, J. W., and Ullrich, S. J. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses wild-type p53. Proc. Natl. Acad. Sci. USA, 87: 6166–6170, 1990.
34. Michalovitz, D., Halevy, O., and Oren, M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell, 62: 671–680,1990.
35. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493–501,1992.
36. Feinberg, A. P., and Vogelstein, B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal. Biochem., 132: 6–13, 1983.
37. Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol, D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res., 54: 3391–3395, 1994.
38. Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024–1027,1995.
39. Halevy, O., Novitch, B. G., Spiccr, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267:1018–1021, 1995.
40. Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A. B., and Mercer, W. E. p53-independent induction of WAF1/C1P1 in human leukemia cells is correlated with growth arrest accompanying monocyte/ macrophage differentiation. Cancer Res., 55: 668–674, 1995.
41. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol., 12: 2866–2871, 1992.
42. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Phrakett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell, 71: 587–597, 1992.
43. Lu, X., and Lane, D. P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell, 75: 765–778, 1993.
44. 1 arrest. Cell, 76: 1013–1024,1994.
45. 1 arrest and apoptosis. Cancer Res., 54: 1169–1174, 1994.
46. Strauss, J. S., DowNing, D. T., Ebling, F. J., and Stewart, M. Sebaceous glands. In: L. A. Goldsmith (ed.), Physiology, Biochemistry, and Molecular Biology of the Skin, p.712. Oxford University Press, 1991.
47. Lipkin, M., Bell, B., and Sherlock, P. Cell proliferation kinetics in the gastrointestinal tract of man. I. Cell renewal in colon and rectum. J. Clin. Invest., 42: 767, 1963.
48. Lipkin, M., Sherlock, P., and Bell, B. Cell proliferation kinetics in the gastrointestinal tract of man. II. Cell renewal in stomach, ileum, colon, and rectum. Gastroenterology, 45: 721, 1963.
49. Gerdes, J., Schwab, U., Lemke, H., and Stein, H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer, 31: 13–20, 1983.
50. Sawhney, N., and Hall, P. A. Ki67: structure, function, and new antibodies. J. Pathol., 168: 161–162, 1992.
51. Lopez, F., Belloc, F., Lacombe, F., Dumain, P., Reiffers, J., Bernard, P., and Boisseau, M. R. The labeling of proliferating cells by Ki67 and MIB-1 antibodies depends on the binding of a nuclear protein to the DNA. Exp. Cell Res., 210: 145–153, 1994.
52. Gerdes, J., Lemke, H., Baisch, H., Wacker, H-H., Schwab, U., and Stein, H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 133: 1710–1715, 1984.
53. Fearon, E. R., and Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell, 61: 759–767, 1990.
54. Rodrigues, N. R., Rowan, A., Smith, M. E. F., Kerr, I. B., Bodmer, W. F., Gannon, J. V., and Lane, D. P. p53 mutations in colorectal cancer. Proc. Natl. Acad. Sci. USA, 87: 7555–7559, 1990.
55. Levine, A. J., Momand, J., and Finlay, C. A. The p53 tumour suppressor gene. Nature (Lond.), 351: 453–456, 1991.
56. Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S., Willson, J. K. V., Hamilton, S., and Vogelstein, B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res., 50: 7717–7722, 1990.
57. Powell, S. M., Zilz, N., Beazer-Barclay, Y., Bryan, T. M., Hamilton, S. R., Thibodeau, S. N., Vogelstein, B., and Kinzler, K. W. APC mutations occur early during colorectal tumorigenesis. Nature (Lond.), 359: 235–237,1992.
58. Rubinfeld, B., Souza, B., Albert, I., Muller, O., Chamberlain, S. H., Masiarz, F. R., Munemitsu, S., and Polakis, P. Association of the APC gene product with β-catenin. Science (Washington DC), 262: 1731–1734, 1993.
59. Su, L-K., Vogelstein, B., and Kinzler, K. W. Association of the APC tumor suppressor protein with catenins. Science (Washington DC), 262: 1734–1737, 1993.